Picture
SEARCH
What are you looking for?
Need help finding what you are looking for? Contact Us
Compare
Free Samples

PUBLISHER: Global Industry Analysts, Inc. | PRODUCT CODE: 1551558

Cover Image

PUBLISHER: Global Industry Analysts, Inc. | PRODUCT CODE: 1551558

Hepatic Encephalopathy (HE) Treatment

PUBLISHED:
PAGES: 283 Pages
DELIVERY TIME: 1-2 business days
REQUEST FREE SAMPLE
REQUEST CUSTOMIZATION
SELECT AN OPTION
PDF (Single User License)
USD 5850
PDF (Global License to Company and its Fully-owned Subsidiaries)
USD 17550

Add to Cart

Description

Table of Contents

Global Hepatic Encephalopathy (HE) Treatment Market to Reach US$2.1 Billion by 2030

The global market for Hepatic Encephalopathy (HE) Treatment estimated at US$1.5 Billion in the year 2023, is expected to reach US$2.1 Billion by 2030, growing at a CAGR of 4.5% over the analysis period 2023-2030. Antibiotics Treatment, one of the segments analyzed in the report, is expected to record a 5.4% CAGR and reach US$785.0 Million by the end of the analysis period. Growth in the Laxatives Treatment segment is estimated at 4.4% CAGR over the analysis period.

The U.S. Market is Estimated at US$418.4 Million While China is Forecast to Grow at 7.6% CAGR

The Hepatic Encephalopathy (HE) Treatment market in the U.S. is estimated at US$418.4 Million in the year 2023. China, the world's second largest economy, is forecast to reach a projected market size of US$431.2 Million by the year 2030 trailing a CAGR of 7.6% over the analysis period 2023-2030. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at a CAGR of 1.7% and 4.8% respectively over the analysis period. Within Europe, Germany is forecast to grow at approximately 2.7% CAGR.

Global Hepatic Encephalopathy (HE) Treatment Market - Key Trends and Drivers Summarized

How is Hepatic Encephalopathy Understood and Diagnosed?

Hepatic Encephalopathy (HE) is a complex neuropsychiatric syndrome resulting from liver dysfunction, often seen in patients with chronic liver disease, particularly cirrhosis. The condition manifests with a spectrum of cognitive, psychiatric, and motor abnormalities due to the liver's inability to detoxify the blood. The buildup of toxic substances like ammonia leads to brain dysfunction, ranging from subtle cognitive impairments to deep coma. Diagnosis typically relies on clinical assessment, supported by laboratory tests measuring blood ammonia levels, neuroimaging, and neuropsychological evaluations. However, the nonspecific nature of early symptoms, such as confusion and forgetfulness, can complicate the timely diagnosis of HE. The classification of HE into different grades, from mild (Grade 1) to severe (Grade 4), allows for a structured approach to its management and underscores the need for timely intervention to prevent progression to more severe stages.

What Are the Emerging Treatment Modalities for Hepatic Encephalopathy?

Treatment of Hepatic Encephalopathy focuses on reducing the production and absorption of toxic substances, especially ammonia, in the gut. Standard therapies include non-absorbable disaccharides like lactulose, which acidify the gut and promote the excretion of ammonia, and antibiotics such as rifaximin, which reduce ammonia-producing bacteria. The combination of these treatments has shown to be effective in both the acute management and long-term prevention of HE episodes. In recent years, the exploration of gut microbiota modulation has gained traction, with probiotics and prebiotics being investigated for their potential to alter gut flora favorably. Additionally, advancements in liver support systems and liver transplantation continue to provide options for patients with refractory HE. Novel agents targeting neuroinflammation and oxidative stress are also under investigation, promising to expand the therapeutic arsenal against HE. As research continues, the integration of these emerging therapies into clinical practice may significantly enhance patient outcomes.

Can Nutritional and Lifestyle Modifications Alter the Course of Hepatic Encephalopathy?

Beyond pharmacological interventions, nutritional and lifestyle modifications play a critical role in the management of Hepatic Encephalopathy. Protein restriction, once widely recommended, is now approached with caution, as adequate protein intake is essential to prevent muscle wasting, which can exacerbate HE. Instead, the emphasis has shifted towards the intake of branched-chain amino acids (BCAAs) that are less likely to be metabolized into ammonia. Additionally, maintaining optimal hydration and avoiding factors that exacerbate liver dysfunction, such as alcohol and certain medications, are essential. Patients are also advised to adopt a low-sodium diet to manage ascites and prevent fluid overload. Regular monitoring and timely adjustment of dietary plans, in conjunction with medical therapy, can help manage HE more effectively. Education on recognizing early symptoms and avoiding potential triggers is crucial for both patients and caregivers, ensuring a proactive approach to managing this chronic condition.

What Is Driving the Growth of the Hepatic Encephalopathy Treatment Market?

The growth in the Hepatic Encephalopathy treatment market is driven by several factors, including the increasing prevalence of liver diseases such as cirrhosis, hepatitis, and non-alcoholic fatty liver disease (NAFLD), which are closely linked to the incidence of HE. The rising global burden of these conditions, fueled by lifestyle changes and aging populations, is a significant market driver. Additionally, advancements in diagnostic technologies that allow for earlier and more accurate detection of HE are propelling the demand for effective treatments. The development of novel therapeutics, including those targeting the gut-liver axis and neuroinflammation, is expanding the treatment landscape and attracting substantial investment in research and development. Furthermore, the growing awareness among healthcare professionals and patients about the importance of managing HE proactively is leading to increased adoption of both traditional and innovative treatments. Lastly, favorable regulatory policies and the availability of better healthcare infrastructure, particularly in emerging markets, are contributing to the market's expansion, making advanced HE therapies more accessible to a broader patient population.

Select Competitors (Total 43 Featured) -

  • AbbVie Inc.,
  • ASKA Pharmaceutical Co., Ltd.
  • Bausch Health Companies Inc.
  • Cosmo Pharmaceuticals NV
  • Eisai Co., Ltd.,
  • Hikma Pharmaceuticals PLC
  • Kannalife Sciences, Inc.
  • Lupin Limited
  • Mallinckrodt Pharmaceuticals
  • Merck & Co., Inc.
  • Norgine B.V.
  • Pfizer Inc.
  • Salix Pharmaceuticals, Inc.
  • Takeda Pharmaceutical Company Limited
  • Umecrine Cognition AB
Show more
Product Code: MCP24640

TABLE OF CONTENTS

I. METHODOLOGY

II. EXECUTIVE SUMMARY

  • 1. MARKET OVERVIEW
    • Influencer Market Insights
    • Global Economic Update
    • Hepatic Encephalopathy (HE) Treatment - Global Key Competitors Percentage Market Share in 2024 (E)
    • Competitive Market Presence - Strong/Active/Niche/Trivial for Players Worldwide in 2024 (E)
  • 2. FOCUS ON SELECT PLAYERS
  • 3. MARKET TRENDS & DRIVERS
    • Emerging Novel Therapies Drive Market Expansion for Hepatic Encephalopathy Treatment Solutions
    • Rising Global Incidence of Liver Disease and Cirrhosis Significantly Accelerates Demand for HE Interventions
    • Increased Public Health Awareness Campaigns Expand the Addressable Market Opportunity for HE Treatments
    • Integration of Telemedicine in HE Management Solutions Drives Widespread Accessibility of Care
    • Focus on Patient-Centric Approaches Generates Growing Demand for Personalized and Innovative Hepatic Encephalopathy Therapies
    • Biopharmaceutical Innovations in Targeted HE Treatments Open New Avenues for High-Precision Care
    • Introduction of Cost-Effective HE Treatment Options Strengthens Market Penetration
  • 4. GLOBAL MARKET PERSPECTIVE
    • TABLE 1: World Hepatic Encephalopathy (HE) Treatment Market Analysis of Annual Sales in US$ Thousand for Years 2014 through 2030
    • TABLE 2: World Recent Past, Current & Future Analysis for Hepatic Encephalopathy (HE) Treatment by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2023 through 2030 and % CAGR
    • TABLE 3: World Historic Review for Hepatic Encephalopathy (HE) Treatment by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 4: World 16-Year Perspective for Hepatic Encephalopathy (HE) Treatment by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets for Years 2014, 2024 & 2030
    • TABLE 5: World Recent Past, Current & Future Analysis for Antibiotics by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2023 through 2030 and % CAGR
    • TABLE 6: World Historic Review for Antibiotics by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 7: World 16-Year Perspective for Antibiotics by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2024 & 2030
    • TABLE 8: World Recent Past, Current & Future Analysis for Laxatives by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2023 through 2030 and % CAGR
    • TABLE 9: World Historic Review for Laxatives by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 10: World 16-Year Perspective for Laxatives by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2024 & 2030
    • TABLE 11: World Recent Past, Current & Future Analysis for L-Ornithine L-Aspartate by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2023 through 2030 and % CAGR
    • TABLE 12: World Historic Review for L-Ornithine L-Aspartate by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 13: World 16-Year Perspective for L-Ornithine L-Aspartate by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2024 & 2030
    • TABLE 14: World Recent Past, Current & Future Analysis for Other Drug Classes by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2023 through 2030 and % CAGR
    • TABLE 15: World Historic Review for Other Drug Classes by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 16: World 16-Year Perspective for Other Drug Classes by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2024 & 2030
    • TABLE 17: World Recent Past, Current & Future Analysis for Hospital Pharmacies by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2023 through 2030 and % CAGR
    • TABLE 18: World Historic Review for Hospital Pharmacies by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 19: World 16-Year Perspective for Hospital Pharmacies by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2024 & 2030
    • TABLE 20: World Recent Past, Current & Future Analysis for Retail Pharmacies by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2023 through 2030 and % CAGR
    • TABLE 21: World Historic Review for Retail Pharmacies by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 22: World 16-Year Perspective for Retail Pharmacies by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2024 & 2030
    • TABLE 23: World Recent Past, Current & Future Analysis for Online Pharmacies by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2023 through 2030 and % CAGR
    • TABLE 24: World Historic Review for Online Pharmacies by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 25: World 16-Year Perspective for Online Pharmacies by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2024 & 2030

III. MARKET ANALYSIS

  • UNITED STATES
    • Hepatic Encephalopathy (HE) Treatment Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United States for 2024 (E)
    • TABLE 26: USA Recent Past, Current & Future Analysis for Hepatic Encephalopathy (HE) Treatment by Drug Class - Antibiotics, Laxatives, L-Ornithine L-Aspartate and Other Drug Classes - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 27: USA Historic Review for Hepatic Encephalopathy (HE) Treatment by Drug Class - Antibiotics, Laxatives, L-Ornithine L-Aspartate and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 28: USA 16-Year Perspective for Hepatic Encephalopathy (HE) Treatment by Drug Class - Percentage Breakdown of Value Sales for Antibiotics, Laxatives, L-Ornithine L-Aspartate and Other Drug Classes for the Years 2014, 2024 & 2030
    • TABLE 29: USA Recent Past, Current & Future Analysis for Hepatic Encephalopathy (HE) Treatment by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 30: USA Historic Review for Hepatic Encephalopathy (HE) Treatment by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 31: USA 16-Year Perspective for Hepatic Encephalopathy (HE) Treatment by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Online Pharmacies for the Years 2014, 2024 & 2030
  • CANADA
    • TABLE 32: Canada Recent Past, Current & Future Analysis for Hepatic Encephalopathy (HE) Treatment by Drug Class - Antibiotics, Laxatives, L-Ornithine L-Aspartate and Other Drug Classes - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 33: Canada Historic Review for Hepatic Encephalopathy (HE) Treatment by Drug Class - Antibiotics, Laxatives, L-Ornithine L-Aspartate and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 34: Canada 16-Year Perspective for Hepatic Encephalopathy (HE) Treatment by Drug Class - Percentage Breakdown of Value Sales for Antibiotics, Laxatives, L-Ornithine L-Aspartate and Other Drug Classes for the Years 2014, 2024 & 2030
    • TABLE 35: Canada Recent Past, Current & Future Analysis for Hepatic Encephalopathy (HE) Treatment by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 36: Canada Historic Review for Hepatic Encephalopathy (HE) Treatment by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 37: Canada 16-Year Perspective for Hepatic Encephalopathy (HE) Treatment by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Online Pharmacies for the Years 2014, 2024 & 2030
  • JAPAN
    • Hepatic Encephalopathy (HE) Treatment Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Japan for 2024 (E)
    • TABLE 38: Japan Recent Past, Current & Future Analysis for Hepatic Encephalopathy (HE) Treatment by Drug Class - Antibiotics, Laxatives, L-Ornithine L-Aspartate and Other Drug Classes - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 39: Japan Historic Review for Hepatic Encephalopathy (HE) Treatment by Drug Class - Antibiotics, Laxatives, L-Ornithine L-Aspartate and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 40: Japan 16-Year Perspective for Hepatic Encephalopathy (HE) Treatment by Drug Class - Percentage Breakdown of Value Sales for Antibiotics, Laxatives, L-Ornithine L-Aspartate and Other Drug Classes for the Years 2014, 2024 & 2030
    • TABLE 41: Japan Recent Past, Current & Future Analysis for Hepatic Encephalopathy (HE) Treatment by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 42: Japan Historic Review for Hepatic Encephalopathy (HE) Treatment by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 43: Japan 16-Year Perspective for Hepatic Encephalopathy (HE) Treatment by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Online Pharmacies for the Years 2014, 2024 & 2030
  • CHINA
    • Hepatic Encephalopathy (HE) Treatment Market Presence - Strong/Active/Niche/Trivial - Key Competitors in China for 2024 (E)
    • TABLE 44: China Recent Past, Current & Future Analysis for Hepatic Encephalopathy (HE) Treatment by Drug Class - Antibiotics, Laxatives, L-Ornithine L-Aspartate and Other Drug Classes - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 45: China Historic Review for Hepatic Encephalopathy (HE) Treatment by Drug Class - Antibiotics, Laxatives, L-Ornithine L-Aspartate and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 46: China 16-Year Perspective for Hepatic Encephalopathy (HE) Treatment by Drug Class - Percentage Breakdown of Value Sales for Antibiotics, Laxatives, L-Ornithine L-Aspartate and Other Drug Classes for the Years 2014, 2024 & 2030
    • TABLE 47: China Recent Past, Current & Future Analysis for Hepatic Encephalopathy (HE) Treatment by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 48: China Historic Review for Hepatic Encephalopathy (HE) Treatment by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 49: China 16-Year Perspective for Hepatic Encephalopathy (HE) Treatment by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Online Pharmacies for the Years 2014, 2024 & 2030
  • EUROPE
    • Hepatic Encephalopathy (HE) Treatment Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Europe for 2024 (E)
    • TABLE 50: Europe Recent Past, Current & Future Analysis for Hepatic Encephalopathy (HE) Treatment by Geographic Region - France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2023 through 2030 and % CAGR
    • TABLE 51: Europe Historic Review for Hepatic Encephalopathy (HE) Treatment by Geographic Region - France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 52: Europe 16-Year Perspective for Hepatic Encephalopathy (HE) Treatment by Geographic Region - Percentage Breakdown of Value Sales for France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets for Years 2014, 2024 & 2030
    • TABLE 53: Europe Recent Past, Current & Future Analysis for Hepatic Encephalopathy (HE) Treatment by Drug Class - Antibiotics, Laxatives, L-Ornithine L-Aspartate and Other Drug Classes - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 54: Europe Historic Review for Hepatic Encephalopathy (HE) Treatment by Drug Class - Antibiotics, Laxatives, L-Ornithine L-Aspartate and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 55: Europe 16-Year Perspective for Hepatic Encephalopathy (HE) Treatment by Drug Class - Percentage Breakdown of Value Sales for Antibiotics, Laxatives, L-Ornithine L-Aspartate and Other Drug Classes for the Years 2014, 2024 & 2030
    • TABLE 56: Europe Recent Past, Current & Future Analysis for Hepatic Encephalopathy (HE) Treatment by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 57: Europe Historic Review for Hepatic Encephalopathy (HE) Treatment by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 58: Europe 16-Year Perspective for Hepatic Encephalopathy (HE) Treatment by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Online Pharmacies for the Years 2014, 2024 & 2030
  • FRANCE
    • Hepatic Encephalopathy (HE) Treatment Market Presence - Strong/Active/Niche/Trivial - Key Competitors in France for 2024 (E)
    • TABLE 59: France Recent Past, Current & Future Analysis for Hepatic Encephalopathy (HE) Treatment by Drug Class - Antibiotics, Laxatives, L-Ornithine L-Aspartate and Other Drug Classes - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 60: France Historic Review for Hepatic Encephalopathy (HE) Treatment by Drug Class - Antibiotics, Laxatives, L-Ornithine L-Aspartate and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 61: France 16-Year Perspective for Hepatic Encephalopathy (HE) Treatment by Drug Class - Percentage Breakdown of Value Sales for Antibiotics, Laxatives, L-Ornithine L-Aspartate and Other Drug Classes for the Years 2014, 2024 & 2030
    • TABLE 62: France Recent Past, Current & Future Analysis for Hepatic Encephalopathy (HE) Treatment by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 63: France Historic Review for Hepatic Encephalopathy (HE) Treatment by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 64: France 16-Year Perspective for Hepatic Encephalopathy (HE) Treatment by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Online Pharmacies for the Years 2014, 2024 & 2030
  • GERMANY
    • Hepatic Encephalopathy (HE) Treatment Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Germany for 2024 (E)
    • TABLE 65: Germany Recent Past, Current & Future Analysis for Hepatic Encephalopathy (HE) Treatment by Drug Class - Antibiotics, Laxatives, L-Ornithine L-Aspartate and Other Drug Classes - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 66: Germany Historic Review for Hepatic Encephalopathy (HE) Treatment by Drug Class - Antibiotics, Laxatives, L-Ornithine L-Aspartate and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 67: Germany 16-Year Perspective for Hepatic Encephalopathy (HE) Treatment by Drug Class - Percentage Breakdown of Value Sales for Antibiotics, Laxatives, L-Ornithine L-Aspartate and Other Drug Classes for the Years 2014, 2024 & 2030
    • TABLE 68: Germany Recent Past, Current & Future Analysis for Hepatic Encephalopathy (HE) Treatment by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 69: Germany Historic Review for Hepatic Encephalopathy (HE) Treatment by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 70: Germany 16-Year Perspective for Hepatic Encephalopathy (HE) Treatment by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Online Pharmacies for the Years 2014, 2024 & 2030
  • ITALY
    • TABLE 71: Italy Recent Past, Current & Future Analysis for Hepatic Encephalopathy (HE) Treatment by Drug Class - Antibiotics, Laxatives, L-Ornithine L-Aspartate and Other Drug Classes - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 72: Italy Historic Review for Hepatic Encephalopathy (HE) Treatment by Drug Class - Antibiotics, Laxatives, L-Ornithine L-Aspartate and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 73: Italy 16-Year Perspective for Hepatic Encephalopathy (HE) Treatment by Drug Class - Percentage Breakdown of Value Sales for Antibiotics, Laxatives, L-Ornithine L-Aspartate and Other Drug Classes for the Years 2014, 2024 & 2030
    • TABLE 74: Italy Recent Past, Current & Future Analysis for Hepatic Encephalopathy (HE) Treatment by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 75: Italy Historic Review for Hepatic Encephalopathy (HE) Treatment by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 76: Italy 16-Year Perspective for Hepatic Encephalopathy (HE) Treatment by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Online Pharmacies for the Years 2014, 2024 & 2030
  • UNITED KINGDOM
    • Hepatic Encephalopathy (HE) Treatment Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United Kingdom for 2024 (E)
    • TABLE 77: UK Recent Past, Current & Future Analysis for Hepatic Encephalopathy (HE) Treatment by Drug Class - Antibiotics, Laxatives, L-Ornithine L-Aspartate and Other Drug Classes - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 78: UK Historic Review for Hepatic Encephalopathy (HE) Treatment by Drug Class - Antibiotics, Laxatives, L-Ornithine L-Aspartate and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 79: UK 16-Year Perspective for Hepatic Encephalopathy (HE) Treatment by Drug Class - Percentage Breakdown of Value Sales for Antibiotics, Laxatives, L-Ornithine L-Aspartate and Other Drug Classes for the Years 2014, 2024 & 2030
    • TABLE 80: UK Recent Past, Current & Future Analysis for Hepatic Encephalopathy (HE) Treatment by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 81: UK Historic Review for Hepatic Encephalopathy (HE) Treatment by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 82: UK 16-Year Perspective for Hepatic Encephalopathy (HE) Treatment by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Online Pharmacies for the Years 2014, 2024 & 2030
  • SPAIN
    • TABLE 83: Spain Recent Past, Current & Future Analysis for Hepatic Encephalopathy (HE) Treatment by Drug Class - Antibiotics, Laxatives, L-Ornithine L-Aspartate and Other Drug Classes - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 84: Spain Historic Review for Hepatic Encephalopathy (HE) Treatment by Drug Class - Antibiotics, Laxatives, L-Ornithine L-Aspartate and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 85: Spain 16-Year Perspective for Hepatic Encephalopathy (HE) Treatment by Drug Class - Percentage Breakdown of Value Sales for Antibiotics, Laxatives, L-Ornithine L-Aspartate and Other Drug Classes for the Years 2014, 2024 & 2030
    • TABLE 86: Spain Recent Past, Current & Future Analysis for Hepatic Encephalopathy (HE) Treatment by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 87: Spain Historic Review for Hepatic Encephalopathy (HE) Treatment by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 88: Spain 16-Year Perspective for Hepatic Encephalopathy (HE) Treatment by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Online Pharmacies for the Years 2014, 2024 & 2030
  • RUSSIA
    • TABLE 89: Russia Recent Past, Current & Future Analysis for Hepatic Encephalopathy (HE) Treatment by Drug Class - Antibiotics, Laxatives, L-Ornithine L-Aspartate and Other Drug Classes - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 90: Russia Historic Review for Hepatic Encephalopathy (HE) Treatment by Drug Class - Antibiotics, Laxatives, L-Ornithine L-Aspartate and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 91: Russia 16-Year Perspective for Hepatic Encephalopathy (HE) Treatment by Drug Class - Percentage Breakdown of Value Sales for Antibiotics, Laxatives, L-Ornithine L-Aspartate and Other Drug Classes for the Years 2014, 2024 & 2030
    • TABLE 92: Russia Recent Past, Current & Future Analysis for Hepatic Encephalopathy (HE) Treatment by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 93: Russia Historic Review for Hepatic Encephalopathy (HE) Treatment by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 94: Russia 16-Year Perspective for Hepatic Encephalopathy (HE) Treatment by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Online Pharmacies for the Years 2014, 2024 & 2030
  • REST OF EUROPE
    • TABLE 95: Rest of Europe Recent Past, Current & Future Analysis for Hepatic Encephalopathy (HE) Treatment by Drug Class - Antibiotics, Laxatives, L-Ornithine L-Aspartate and Other Drug Classes - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 96: Rest of Europe Historic Review for Hepatic Encephalopathy (HE) Treatment by Drug Class - Antibiotics, Laxatives, L-Ornithine L-Aspartate and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 97: Rest of Europe 16-Year Perspective for Hepatic Encephalopathy (HE) Treatment by Drug Class - Percentage Breakdown of Value Sales for Antibiotics, Laxatives, L-Ornithine L-Aspartate and Other Drug Classes for the Years 2014, 2024 & 2030
    • TABLE 98: Rest of Europe Recent Past, Current & Future Analysis for Hepatic Encephalopathy (HE) Treatment by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 99: Rest of Europe Historic Review for Hepatic Encephalopathy (HE) Treatment by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 100: Rest of Europe 16-Year Perspective for Hepatic Encephalopathy (HE) Treatment by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Online Pharmacies for the Years 2014, 2024 & 2030
  • ASIA-PACIFIC
    • Hepatic Encephalopathy (HE) Treatment Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Asia-Pacific for 2024 (E)
    • TABLE 101: Asia-Pacific Recent Past, Current & Future Analysis for Hepatic Encephalopathy (HE) Treatment by Geographic Region - Australia, India, South Korea and Rest of Asia-Pacific Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2023 through 2030 and % CAGR
    • TABLE 102: Asia-Pacific Historic Review for Hepatic Encephalopathy (HE) Treatment by Geographic Region - Australia, India, South Korea and Rest of Asia-Pacific Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 103: Asia-Pacific 16-Year Perspective for Hepatic Encephalopathy (HE) Treatment by Geographic Region - Percentage Breakdown of Value Sales for Australia, India, South Korea and Rest of Asia-Pacific Markets for Years 2014, 2024 & 2030
    • TABLE 104: Asia-Pacific Recent Past, Current & Future Analysis for Hepatic Encephalopathy (HE) Treatment by Drug Class - Antibiotics, Laxatives, L-Ornithine L-Aspartate and Other Drug Classes - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 105: Asia-Pacific Historic Review for Hepatic Encephalopathy (HE) Treatment by Drug Class - Antibiotics, Laxatives, L-Ornithine L-Aspartate and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 106: Asia-Pacific 16-Year Perspective for Hepatic Encephalopathy (HE) Treatment by Drug Class - Percentage Breakdown of Value Sales for Antibiotics, Laxatives, L-Ornithine L-Aspartate and Other Drug Classes for the Years 2014, 2024 & 2030
    • TABLE 107: Asia-Pacific Recent Past, Current & Future Analysis for Hepatic Encephalopathy (HE) Treatment by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 108: Asia-Pacific Historic Review for Hepatic Encephalopathy (HE) Treatment by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 109: Asia-Pacific 16-Year Perspective for Hepatic Encephalopathy (HE) Treatment by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Online Pharmacies for the Years 2014, 2024 & 2030
  • AUSTRALIA
    • Hepatic Encephalopathy (HE) Treatment Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Australia for 2024 (E)
    • TABLE 110: Australia Recent Past, Current & Future Analysis for Hepatic Encephalopathy (HE) Treatment by Drug Class - Antibiotics, Laxatives, L-Ornithine L-Aspartate and Other Drug Classes - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 111: Australia Historic Review for Hepatic Encephalopathy (HE) Treatment by Drug Class - Antibiotics, Laxatives, L-Ornithine L-Aspartate and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 112: Australia 16-Year Perspective for Hepatic Encephalopathy (HE) Treatment by Drug Class - Percentage Breakdown of Value Sales for Antibiotics, Laxatives, L-Ornithine L-Aspartate and Other Drug Classes for the Years 2014, 2024 & 2030
    • TABLE 113: Australia Recent Past, Current & Future Analysis for Hepatic Encephalopathy (HE) Treatment by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 114: Australia Historic Review for Hepatic Encephalopathy (HE) Treatment by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 115: Australia 16-Year Perspective for Hepatic Encephalopathy (HE) Treatment by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Online Pharmacies for the Years 2014, 2024 & 2030
  • INDIA
    • Hepatic Encephalopathy (HE) Treatment Market Presence - Strong/Active/Niche/Trivial - Key Competitors in India for 2024 (E)
    • TABLE 116: India Recent Past, Current & Future Analysis for Hepatic Encephalopathy (HE) Treatment by Drug Class - Antibiotics, Laxatives, L-Ornithine L-Aspartate and Other Drug Classes - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 117: India Historic Review for Hepatic Encephalopathy (HE) Treatment by Drug Class - Antibiotics, Laxatives, L-Ornithine L-Aspartate and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 118: India 16-Year Perspective for Hepatic Encephalopathy (HE) Treatment by Drug Class - Percentage Breakdown of Value Sales for Antibiotics, Laxatives, L-Ornithine L-Aspartate and Other Drug Classes for the Years 2014, 2024 & 2030
    • TABLE 119: India Recent Past, Current & Future Analysis for Hepatic Encephalopathy (HE) Treatment by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 120: India Historic Review for Hepatic Encephalopathy (HE) Treatment by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 121: India 16-Year Perspective for Hepatic Encephalopathy (HE) Treatment by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Online Pharmacies for the Years 2014, 2024 & 2030
  • SOUTH KOREA
    • TABLE 122: South Korea Recent Past, Current & Future Analysis for Hepatic Encephalopathy (HE) Treatment by Drug Class - Antibiotics, Laxatives, L-Ornithine L-Aspartate and Other Drug Classes - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 123: South Korea Historic Review for Hepatic Encephalopathy (HE) Treatment by Drug Class - Antibiotics, Laxatives, L-Ornithine L-Aspartate and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 124: South Korea 16-Year Perspective for Hepatic Encephalopathy (HE) Treatment by Drug Class - Percentage Breakdown of Value Sales for Antibiotics, Laxatives, L-Ornithine L-Aspartate and Other Drug Classes for the Years 2014, 2024 & 2030
    • TABLE 125: South Korea Recent Past, Current & Future Analysis for Hepatic Encephalopathy (HE) Treatment by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 126: South Korea Historic Review for Hepatic Encephalopathy (HE) Treatment by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 127: South Korea 16-Year Perspective for Hepatic Encephalopathy (HE) Treatment by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Online Pharmacies for the Years 2014, 2024 & 2030
  • REST OF ASIA-PACIFIC
    • TABLE 128: Rest of Asia-Pacific Recent Past, Current & Future Analysis for Hepatic Encephalopathy (HE) Treatment by Drug Class - Antibiotics, Laxatives, L-Ornithine L-Aspartate and Other Drug Classes - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 129: Rest of Asia-Pacific Historic Review for Hepatic Encephalopathy (HE) Treatment by Drug Class - Antibiotics, Laxatives, L-Ornithine L-Aspartate and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 130: Rest of Asia-Pacific 16-Year Perspective for Hepatic Encephalopathy (HE) Treatment by Drug Class - Percentage Breakdown of Value Sales for Antibiotics, Laxatives, L-Ornithine L-Aspartate and Other Drug Classes for the Years 2014, 2024 & 2030
    • TABLE 131: Rest of Asia-Pacific Recent Past, Current & Future Analysis for Hepatic Encephalopathy (HE) Treatment by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 132: Rest of Asia-Pacific Historic Review for Hepatic Encephalopathy (HE) Treatment by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 133: Rest of Asia-Pacific 16-Year Perspective for Hepatic Encephalopathy (HE) Treatment by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Online Pharmacies for the Years 2014, 2024 & 2030
  • LATIN AMERICA
    • Hepatic Encephalopathy (HE) Treatment Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Latin America for 2024 (E)
    • TABLE 134: Latin America Recent Past, Current & Future Analysis for Hepatic Encephalopathy (HE) Treatment by Geographic Region - Argentina, Brazil, Mexico and Rest of Latin America Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2023 through 2030 and % CAGR
    • TABLE 135: Latin America Historic Review for Hepatic Encephalopathy (HE) Treatment by Geographic Region - Argentina, Brazil, Mexico and Rest of Latin America Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 136: Latin America 16-Year Perspective for Hepatic Encephalopathy (HE) Treatment by Geographic Region - Percentage Breakdown of Value Sales for Argentina, Brazil, Mexico and Rest of Latin America Markets for Years 2014, 2024 & 2030
    • TABLE 137: Latin America Recent Past, Current & Future Analysis for Hepatic Encephalopathy (HE) Treatment by Drug Class - Antibiotics, Laxatives, L-Ornithine L-Aspartate and Other Drug Classes - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 138: Latin America Historic Review for Hepatic Encephalopathy (HE) Treatment by Drug Class - Antibiotics, Laxatives, L-Ornithine L-Aspartate and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 139: Latin America 16-Year Perspective for Hepatic Encephalopathy (HE) Treatment by Drug Class - Percentage Breakdown of Value Sales for Antibiotics, Laxatives, L-Ornithine L-Aspartate and Other Drug Classes for the Years 2014, 2024 & 2030
    • TABLE 140: Latin America Recent Past, Current & Future Analysis for Hepatic Encephalopathy (HE) Treatment by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 141: Latin America Historic Review for Hepatic Encephalopathy (HE) Treatment by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 142: Latin America 16-Year Perspective for Hepatic Encephalopathy (HE) Treatment by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Online Pharmacies for the Years 2014, 2024 & 2030
  • ARGENTINA
    • TABLE 143: Argentina Recent Past, Current & Future Analysis for Hepatic Encephalopathy (HE) Treatment by Drug Class - Antibiotics, Laxatives, L-Ornithine L-Aspartate and Other Drug Classes - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 144: Argentina Historic Review for Hepatic Encephalopathy (HE) Treatment by Drug Class - Antibiotics, Laxatives, L-Ornithine L-Aspartate and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 145: Argentina 16-Year Perspective for Hepatic Encephalopathy (HE) Treatment by Drug Class - Percentage Breakdown of Value Sales for Antibiotics, Laxatives, L-Ornithine L-Aspartate and Other Drug Classes for the Years 2014, 2024 & 2030
    • TABLE 146: Argentina Recent Past, Current & Future Analysis for Hepatic Encephalopathy (HE) Treatment by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 147: Argentina Historic Review for Hepatic Encephalopathy (HE) Treatment by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 148: Argentina 16-Year Perspective for Hepatic Encephalopathy (HE) Treatment by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Online Pharmacies for the Years 2014, 2024 & 2030
  • BRAZIL
    • TABLE 149: Brazil Recent Past, Current & Future Analysis for Hepatic Encephalopathy (HE) Treatment by Drug Class - Antibiotics, Laxatives, L-Ornithine L-Aspartate and Other Drug Classes - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 150: Brazil Historic Review for Hepatic Encephalopathy (HE) Treatment by Drug Class - Antibiotics, Laxatives, L-Ornithine L-Aspartate and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 151: Brazil 16-Year Perspective for Hepatic Encephalopathy (HE) Treatment by Drug Class - Percentage Breakdown of Value Sales for Antibiotics, Laxatives, L-Ornithine L-Aspartate and Other Drug Classes for the Years 2014, 2024 & 2030
    • TABLE 152: Brazil Recent Past, Current & Future Analysis for Hepatic Encephalopathy (HE) Treatment by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 153: Brazil Historic Review for Hepatic Encephalopathy (HE) Treatment by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 154: Brazil 16-Year Perspective for Hepatic Encephalopathy (HE) Treatment by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Online Pharmacies for the Years 2014, 2024 & 2030
  • MEXICO
    • TABLE 155: Mexico Recent Past, Current & Future Analysis for Hepatic Encephalopathy (HE) Treatment by Drug Class - Antibiotics, Laxatives, L-Ornithine L-Aspartate and Other Drug Classes - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 156: Mexico Historic Review for Hepatic Encephalopathy (HE) Treatment by Drug Class - Antibiotics, Laxatives, L-Ornithine L-Aspartate and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 157: Mexico 16-Year Perspective for Hepatic Encephalopathy (HE) Treatment by Drug Class - Percentage Breakdown of Value Sales for Antibiotics, Laxatives, L-Ornithine L-Aspartate and Other Drug Classes for the Years 2014, 2024 & 2030
    • TABLE 158: Mexico Recent Past, Current & Future Analysis for Hepatic Encephalopathy (HE) Treatment by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 159: Mexico Historic Review for Hepatic Encephalopathy (HE) Treatment by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 160: Mexico 16-Year Perspective for Hepatic Encephalopathy (HE) Treatment by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Online Pharmacies for the Years 2014, 2024 & 2030
  • REST OF LATIN AMERICA
    • TABLE 161: Rest of Latin America Recent Past, Current & Future Analysis for Hepatic Encephalopathy (HE) Treatment by Drug Class - Antibiotics, Laxatives, L-Ornithine L-Aspartate and Other Drug Classes - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 162: Rest of Latin America Historic Review for Hepatic Encephalopathy (HE) Treatment by Drug Class - Antibiotics, Laxatives, L-Ornithine L-Aspartate and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 163: Rest of Latin America 16-Year Perspective for Hepatic Encephalopathy (HE) Treatment by Drug Class - Percentage Breakdown of Value Sales for Antibiotics, Laxatives, L-Ornithine L-Aspartate and Other Drug Classes for the Years 2014, 2024 & 2030
    • TABLE 164: Rest of Latin America Recent Past, Current & Future Analysis for Hepatic Encephalopathy (HE) Treatment by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 165: Rest of Latin America Historic Review for Hepatic Encephalopathy (HE) Treatment by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 166: Rest of Latin America 16-Year Perspective for Hepatic Encephalopathy (HE) Treatment by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Online Pharmacies for the Years 2014, 2024 & 2030
  • MIDDLE EAST
    • Hepatic Encephalopathy (HE) Treatment Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Middle East for 2024 (E)
    • TABLE 167: Middle East Recent Past, Current & Future Analysis for Hepatic Encephalopathy (HE) Treatment by Geographic Region - Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2023 through 2030 and % CAGR
    • TABLE 168: Middle East Historic Review for Hepatic Encephalopathy (HE) Treatment by Geographic Region - Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 169: Middle East 16-Year Perspective for Hepatic Encephalopathy (HE) Treatment by Geographic Region - Percentage Breakdown of Value Sales for Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets for Years 2014, 2024 & 2030
    • TABLE 170: Middle East Recent Past, Current & Future Analysis for Hepatic Encephalopathy (HE) Treatment by Drug Class - Antibiotics, Laxatives, L-Ornithine L-Aspartate and Other Drug Classes - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 171: Middle East Historic Review for Hepatic Encephalopathy (HE) Treatment by Drug Class - Antibiotics, Laxatives, L-Ornithine L-Aspartate and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 172: Middle East 16-Year Perspective for Hepatic Encephalopathy (HE) Treatment by Drug Class - Percentage Breakdown of Value Sales for Antibiotics, Laxatives, L-Ornithine L-Aspartate and Other Drug Classes for the Years 2014, 2024 & 2030
    • TABLE 173: Middle East Recent Past, Current & Future Analysis for Hepatic Encephalopathy (HE) Treatment by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 174: Middle East Historic Review for Hepatic Encephalopathy (HE) Treatment by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 175: Middle East 16-Year Perspective for Hepatic Encephalopathy (HE) Treatment by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Online Pharmacies for the Years 2014, 2024 & 2030
  • IRAN
    • TABLE 176: Iran Recent Past, Current & Future Analysis for Hepatic Encephalopathy (HE) Treatment by Drug Class - Antibiotics, Laxatives, L-Ornithine L-Aspartate and Other Drug Classes - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 177: Iran Historic Review for Hepatic Encephalopathy (HE) Treatment by Drug Class - Antibiotics, Laxatives, L-Ornithine L-Aspartate and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 178: Iran 16-Year Perspective for Hepatic Encephalopathy (HE) Treatment by Drug Class - Percentage Breakdown of Value Sales for Antibiotics, Laxatives, L-Ornithine L-Aspartate and Other Drug Classes for the Years 2014, 2024 & 2030
    • TABLE 179: Iran Recent Past, Current & Future Analysis for Hepatic Encephalopathy (HE) Treatment by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 180: Iran Historic Review for Hepatic Encephalopathy (HE) Treatment by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 181: Iran 16-Year Perspective for Hepatic Encephalopathy (HE) Treatment by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Online Pharmacies for the Years 2014, 2024 & 2030
  • ISRAEL
    • TABLE 182: Israel Recent Past, Current & Future Analysis for Hepatic Encephalopathy (HE) Treatment by Drug Class - Antibiotics, Laxatives, L-Ornithine L-Aspartate and Other Drug Classes - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 183: Israel Historic Review for Hepatic Encephalopathy (HE) Treatment by Drug Class - Antibiotics, Laxatives, L-Ornithine L-Aspartate and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 184: Israel 16-Year Perspective for Hepatic Encephalopathy (HE) Treatment by Drug Class - Percentage Breakdown of Value Sales for Antibiotics, Laxatives, L-Ornithine L-Aspartate and Other Drug Classes for the Years 2014, 2024 & 2030
    • TABLE 185: Israel Recent Past, Current & Future Analysis for Hepatic Encephalopathy (HE) Treatment by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 186: Israel Historic Review for Hepatic Encephalopathy (HE) Treatment by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 187: Israel 16-Year Perspective for Hepatic Encephalopathy (HE) Treatment by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Online Pharmacies for the Years 2014, 2024 & 2030
  • SAUDI ARABIA
    • TABLE 188: Saudi Arabia Recent Past, Current & Future Analysis for Hepatic Encephalopathy (HE) Treatment by Drug Class - Antibiotics, Laxatives, L-Ornithine L-Aspartate and Other Drug Classes - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 189: Saudi Arabia Historic Review for Hepatic Encephalopathy (HE) Treatment by Drug Class - Antibiotics, Laxatives, L-Ornithine L-Aspartate and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 190: Saudi Arabia 16-Year Perspective for Hepatic Encephalopathy (HE) Treatment by Drug Class - Percentage Breakdown of Value Sales for Antibiotics, Laxatives, L-Ornithine L-Aspartate and Other Drug Classes for the Years 2014, 2024 & 2030
    • TABLE 191: Saudi Arabia Recent Past, Current & Future Analysis for Hepatic Encephalopathy (HE) Treatment by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 192: Saudi Arabia Historic Review for Hepatic Encephalopathy (HE) Treatment by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 193: Saudi Arabia 16-Year Perspective for Hepatic Encephalopathy (HE) Treatment by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Online Pharmacies for the Years 2014, 2024 & 2030
  • UNITED ARAB EMIRATES
    • TABLE 194: UAE Recent Past, Current & Future Analysis for Hepatic Encephalopathy (HE) Treatment by Drug Class - Antibiotics, Laxatives, L-Ornithine L-Aspartate and Other Drug Classes - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 195: UAE Historic Review for Hepatic Encephalopathy (HE) Treatment by Drug Class - Antibiotics, Laxatives, L-Ornithine L-Aspartate and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 196: UAE 16-Year Perspective for Hepatic Encephalopathy (HE) Treatment by Drug Class - Percentage Breakdown of Value Sales for Antibiotics, Laxatives, L-Ornithine L-Aspartate and Other Drug Classes for the Years 2014, 2024 & 2030
    • TABLE 197: UAE Recent Past, Current & Future Analysis for Hepatic Encephalopathy (HE) Treatment by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 198: UAE Historic Review for Hepatic Encephalopathy (HE) Treatment by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 199: UAE 16-Year Perspective for Hepatic Encephalopathy (HE) Treatment by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Online Pharmacies for the Years 2014, 2024 & 2030
  • REST OF MIDDLE EAST
    • TABLE 200: Rest of Middle East Recent Past, Current & Future Analysis for Hepatic Encephalopathy (HE) Treatment by Drug Class - Antibiotics, Laxatives, L-Ornithine L-Aspartate and Other Drug Classes - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 201: Rest of Middle East Historic Review for Hepatic Encephalopathy (HE) Treatment by Drug Class - Antibiotics, Laxatives, L-Ornithine L-Aspartate and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 202: Rest of Middle East 16-Year Perspective for Hepatic Encephalopathy (HE) Treatment by Drug Class - Percentage Breakdown of Value Sales for Antibiotics, Laxatives, L-Ornithine L-Aspartate and Other Drug Classes for the Years 2014, 2024 & 2030
    • TABLE 203: Rest of Middle East Recent Past, Current & Future Analysis for Hepatic Encephalopathy (HE) Treatment by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 204: Rest of Middle East Historic Review for Hepatic Encephalopathy (HE) Treatment by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 205: Rest of Middle East 16-Year Perspective for Hepatic Encephalopathy (HE) Treatment by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Online Pharmacies for the Years 2014, 2024 & 2030
  • AFRICA
    • Hepatic Encephalopathy (HE) Treatment Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Africa for 2024 (E)
    • TABLE 206: Africa Recent Past, Current & Future Analysis for Hepatic Encephalopathy (HE) Treatment by Drug Class - Antibiotics, Laxatives, L-Ornithine L-Aspartate and Other Drug Classes - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 207: Africa Historic Review for Hepatic Encephalopathy (HE) Treatment by Drug Class - Antibiotics, Laxatives, L-Ornithine L-Aspartate and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 208: Africa 16-Year Perspective for Hepatic Encephalopathy (HE) Treatment by Drug Class - Percentage Breakdown of Value Sales for Antibiotics, Laxatives, L-Ornithine L-Aspartate and Other Drug Classes for the Years 2014, 2024 & 2030
    • TABLE 209: Africa Recent Past, Current & Future Analysis for Hepatic Encephalopathy (HE) Treatment by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 210: Africa Historic Review for Hepatic Encephalopathy (HE) Treatment by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 211: Africa 16-Year Perspective for Hepatic Encephalopathy (HE) Treatment by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Online Pharmacies for the Years 2014, 2024 & 2030

IV. COMPETITION

Show more
Have a question?
Picture

Jeroen Van Heghe

Manager - EMEA

+32-2-535-7543

Picture

Christine Sirois

Manager - Americas

+1-860-674-8796

Questions? Please give us a call or visit the contact form.
Contact Us +1-866-353-3335
Hi, how can we help?
Contact us!